V K Shah
Overview
Explore the profile of V K Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
1479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah S, Shah V, Thakur M, Sembhi K
JACC Cardiovasc Interv
. 2020 Sep;
13(19):e177-e178.
PMID: 32950417
No abstract available.
2.
Shah V, Shalia K
Indian Heart J
. 2018 Jul;
70(3):433-438.
PMID: 29961464
Return of blood flow after periodic ischemia is often accompanied by myocardial injury, commonly known as lethal reperfusion injury (RI). Experimental studies have shown that 50% of muscle die of...
3.
Shalia K, Savant S, Haldankar V, Nandu T, Pawar P, Divekar S, et al.
Indian J Clin Biochem
. 2013 Jan;
27(1):74-82.
PMID: 23277716
To analyse the association of high sensitivity C-reactive (hsCRP) protein levels and -717A/G single nucleotide polymorphism of CRP with acute myocardial infarction (AMI) in the Indian population. Study population included...
4.
Shalia K, Shah V, Mashru M, Soneji S, Vasvani J, Payannavar S, et al.
Indian J Clin Biochem
. 2012 Oct;
25(2):133-40.
PMID: 23105899
Matrix metalloproteinases (MMPs) play important role in the pathogenesis of coronary artery disease (CAD). 5A allele of -1612 5A/6A polymorphism of MMP-3 is associated with two fold higher activity than...
5.
Shalia K, Shah V, Mashru M, Soneji S, Vasvani J, Payannavar S, et al.
Indian J Clin Biochem
. 2012 Oct;
25(1):20-8.
PMID: 23105879
The study aimed to analyze the circulating levels of thrombotic and haemostatic components; tissue factor, tissue factor pathway inhibitor, tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with acute...
6.
Shah V, Shalia K
Stem Cells Int
. 2011 Aug;
2011:536758.
PMID: 21804827
Stem cell therapy for conditions characterized by myocyte loss in myocardial infarction and heart failure is intuitively appealing. Stem cells from various sources, including heart itself in preclinical and animal...
7.
Rangaraj P, Ruttimann-Johnson C, Shah V, Ludden P
J Biol Chem
. 2001 Mar;
276(19):15968-74.
PMID: 11279153
Iron-molybdenum cofactor (FeMo-co) biosynthesis involves the participation of several proteins. We have used (55)Fe-labeled NifB-co, the specific iron and sulfur donor to FeMo-co, to investigate the accumulation of protein-bound precursors...
8.
Ruttimann-Johnson C, Rangaraj P, Shah V, Ludden P
J Biol Chem
. 2000 Oct;
276(6):4522-6.
PMID: 11053414
A vanadium- and iron-containing cluster has been shown previously to accumulate on VnfX in the Azotobacter vinelandii mutant strain CA11.1 (DeltanifHDKvnfDGK::spc). In the present study, we show the homocitrate-dependent transfer...
9.
Rangaraj P, Ryle M, Lanzilotta W, Goodwin P, Dean D, Shah V, et al.
J Biol Chem
. 1999 Oct;
274(41):29413-9.
PMID: 10506203
Besides serving as the obligate electron donor to dinitrogenase during nitrogenase turnover, dinitrogenase reductase (NifH) is required for the biosynthesis of the iron-molybdenum cofactor (FeMo-co) and for the maturation of...
10.
Rangaraj P, Ryle M, Lanzilotta W, Ludden P, Shah V
J Biol Chem
. 1999 Jul;
274(28):19778-84.
PMID: 10391920
NifH has three different roles in the nitrogenase enzyme system. Apart from serving as the physiological electron donor to dinitrogenase, NifH is involved in iron-molybdenum cofactor (FeMo-co) biosynthesis and in...